

## **Global Cardiac Biomarkers Market - Types, Applications and Testing Locations**

Market Report | 2025-08-01 | 256 pages | Industry Experts

### **AVAILABLE LICENSES:**

- Single user licence (PDF) \$4500.00
- Enterprise Electronic (PDF) \$7200.00

### **Report description:**

Global Cardiac Biomarkers Market Trends and Outlook

Cardiac biomarkers are critical diagnostic tools released into the bloodstream during heart damage, stress, or ischemia, widely used for detecting conditions such as myocardial infarction (MI), acute coronary syndromes (ACS), and heart failure (HF). Among these, Troponins I and T are the gold standard due to their high specificity and extended diagnostic window. BNP and NT-proBNP are pivotal in heart failure diagnosis by indicating ventricular strain, while other markers like CK-MB, myoglobin, IMA, H-FABP, hs-CRP, and emerging biomarkers such as copeptin offer complementary insights. High-sensitivity assays, particularly for troponins and inflammatory markers, have advanced early detection and long-term risk prediction, playing a central role in modern cardiac care.

Valued at US\$22.7 billion in 2025, the global cardiac biomarkers market is projected to reach US\$57.5 billion by 2032, growing at a CAGR of 14.2%. Key growth drivers include the rising global burden of cardiovascular diseases, rapid adoption of point-of-care (PoC) testing, and technological advancements in high-sensitivity assays. The market is further supported by the shift toward personalized medicine, increasing investment in AI-integrated diagnostics, and expanding access to healthcare in emerging regions. Aging populations, sedentary lifestyles, and the global rise in comorbidities such as hypertension and diabetes are broadening the patient base, while strong regulatory backing and improved reimbursement policies are accelerating adoption and innovation across both developed and developing markets.

Cardiac Biomarkers Regional Market Analysis

North America dominates the global cardiac biomarkers market, accounting for a 41.8% share in 2025, driven by a high prevalence of cardiovascular diseases, robust healthcare infrastructure, and strong R&D investment. The United States leads the region due to early adoption of high-sensitivity assays, favorable reimbursement, and regulatory support from the FDA. Europe follows with accelerated growth attributed to an aging population, increased incidence of acute coronary syndrome, and widespread use of biomarkers for early diagnosis. Conversely, Asia Pacific is the fastest-growing region, expected to achieve a compound annual growth rate (CAGR) of over 16% from 2025 to 2032. This growth is fueled by improved healthcare infrastructure, increasing disposable incomes, and a significant burden of cardiovascular disease (CVD) in countries like China and

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

India. China's leadership in this market is bolstered by national health initiatives and improved diagnostic accuracy. In contrast, India is experiencing rapid growth due to urbanization and government-supported health reforms. The expansion of the market in this region is further driven by increasing awareness, medical tourism, and the strategic focus of global manufacturers.

### Cardiac Biomarkers Market Analysis by Type

Troponin accounts for the largest portion of the global cardiac biomarkers market, with an estimated market share of 35% in 2025. Its dominance is driven by exceptional sensitivity and specificity in detecting myocardial injury, making it the gold standard for diagnosing acute coronary syndromes (ACS) and myocardial infarctions (MI). High-sensitivity troponin assays enable early and accurate detection of cardiac events, facilitating timely clinical interventions. The American Heart Association (AHA) recommends troponin as the preferred biomarker, warning against less specific alternatives such as CK-MB and myoglobin. Troponin I and T levels remain elevated for days post-event, aiding in both diagnosis and prognosis. On the other hand, the BNP and NT-proBNP segment is expected to witness the fastest CAGR of 15.9% during the forecast period 2025-2032. Natriuretic peptides are crucial in diagnosing and managing heart failure, helping to differentiate between cardiac and non-cardiac conditions and guiding treatment decisions. With the global burden of heart failure on the rise, demand for BNP-based tests is accelerating. Their prognostic value in risk stratification and recurrence prediction fuels adoption across emergency and chronic care settings.

### Cardiac Biomarkers Market Analysis by Application

Myocardial Infarction (MI) is the leading application segment in the cardiac biomarkers market, accounting for a 41.6% share in 2025. This dominance is driven by the rising global incidence of MI, necessitating rapid and accurate diagnosis to guide timely interventions. Cardiac biomarkers such as troponins, CK-MB, and myoglobin are essential for detecting myocardial injury, providing greater diagnostic accuracy than ECGs or clinical symptom history alone. The growing use of POC testing in emergency departments underscores the critical role of biomarkers in early detection and risk stratification. In contrast, the Acute Coronary Syndrome (ACS) segment is anticipated to achieve the fastest CAGR of 15.4% from 2025 to 2032, driven by the growing adoption of accelerated diagnostic protocols and payer incentives aimed at reducing unnecessary hospital admissions. Rising disease prevalence, especially in low- and middle-income countries, along with the integration of biomarker panels into chronic care and ASCVD management, is further propelling demand. ACS diagnostics increasingly rely on high-sensitivity troponin assays, enabling rapid triage and improved clinical outcomes in high-risk populations.

### Cardiac Biomarkers Market Analysis by Location of Testing

The laboratory testing segment dominates the global cardiac biomarkers market, capturing a 62.2% share in 2025 due to its high accuracy, scalability, and adherence to standardized protocols. Clinical labs support high-volume testing with broad biomarker panels and robust quality control, making them the preferred choice for confirmatory diagnostics. Despite longer turnaround times, their diagnostic precision supports critical decision-making in hospitals and reference centers. Conversely, the Point-of-Care (PoC) testing segment is projected to grow at the fastest CAGR of 15.3% from 2025 to 2032, driven by demand for rapid, bedside diagnostics in emergency and decentralized settings. PoC tests enable faster clinical decisions, enhance patient triage, and are increasingly adopted in elderly care, home settings, and low-resource environments. However, limitations around accuracy and throughput remain a challenge. Continuous advancements in POC platforms and cost pressures in healthcare are expected to accelerate their adoption.

### Cardiac Biomarkers Market Report Scope

This global report on Cardiac Biomarkers analyzes the market based on type, application, and location of testing for the period 2021-2032 with projections from 2025 to 2032 in terms of value in US\$. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

where the market is progressing.

#### Key Metrics

Historical Period: 2022-2024

Base Year: 2025

Forecast Period: 2025-2032

Units: Value market in US\$

Companies Mentioned: 10+

#### Cardiac Biomarkers Market by Geographic Region

- North America (The United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, and Rest of Europe)
- Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, and Rest of South America)
- Rest of World

#### Cardiac Biomarkers Market by Type

- Troponins (I and T)
- B-type Natriuretic Peptide (BNP) / NT-proBNP
- Creatine Kinase-MB (CK-MB)
- Myoglobin
- Ischemia-Modified Albumin (IMA)
- Other Types (Heart-Type Fatty Acid Binding Protein (H-FABP), High-Sensitivity C-Reactive Protein (hs-CRP), Copeptin, and Other Emerging Biomarkers)

#### Cardiac Biomarkers Market by Application

- Myocardial Infarction (MI)
- Congestive Heart Failure (CHF)
- Acute Coronary Syndrome (ACS)
- Atherosclerosis
- Other Applications (Including Arrhythmia, Cardiomyopathies, Myocarditis, Pericarditis, Post-operative Monitoring, Cardiotoxicity, and Cardiac Wellness Programs)

#### Cardiac Biomarkers Market by Location of Testing

- Laboratory Testing
- Point-of-Care (POC) Testing

### **Table of Contents:**

#### PART A: GLOBAL MARKET PERSPECTIVE

##### 1. INTRODUCTION

- Product Outline
- Cardiac Biomarkers Defined
- Cardiac Biomarker Types
  - o□Troponins (I and T)
  - o□B-type Natriuretic Peptide (BNP) / NT-proBNP
  - o□Creatine Kinase-MB (CK-MB)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Myoglobin
- o Ischemia-Modified Albumin (IMA)
- o Other Types (Heart-Type Fatty Acid Binding Protein (H-FABP), High-Sensitivity C-Reactive Protein (hs-CRP), Copeptin, and Other Emerging Biomarkers)
  - Cardiac Biomarker Applications
  - o Myocardial Infarction (MI)
  - o Congestive Heart Failure (CHF)
  - o Acute Coronary Syndrome (ACS)
  - o Atherosclerosis
  - o Other Applications (Including Arrhythmia, Cardiomyopathies, Myocarditis, Pericarditis, Post-operative Monitoring, Cardiotoxicity, and Cardiac Wellness Programs)
    - Cardiac Biomarker Location of Testing
    - o Laboratory Testing
    - o Point-of-Care (POC) Testing
- 2. Key Market Trends
- 3. Key Market Players
  - Abbott laboratories
  - Biomerieux SA
  - Bio-Rad Laboratories, Inc.
  - Creative Diagnostics
  - Danaher Corporation
  - F. Hoffmann-La Roche Ltd.
  - Life Diagnostics, Inc.
  - QuidelOrtho Corporation
  - Randox Laboratories Ltd.
  - Siemens Healthineers AG
  - Thermo Fisher Scientific Inc.
- 4. Key Business & Product Trends
- 5. Global Market Overview
  - Global Cardiac Biomarkers Market Overview by Type
    - o Cardiac Biomarkers Type Market Overview by Global Region
      - Troponins (I and T)
      - B-type Natriuretic Peptide (BNP) / NT-proBNP
      - Creatine Kinase-MB (CK-MB)
      - Myoglobin
      - Ischemia-Modified Albumin (IMA)
      - Other Types
        - Global Cardiac Biomarkers Market Overview by Application
          - o Cardiac Biomarkers Application Market Overview by Global Region
            - Myocardial Infarction (MI)
            - Congestive Heart Failure (CHF)
            - Acute Coronary Syndrome (ACS)
            - Atherosclerosis
            - Other Applications
              - Global Cardiac Biomarkers Market Overview by Location of Testing
                - o Cardiac Biomarkers Location of Testing Market Overview by Global Region
                  - Laboratory Testing

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-□Point-of-Care (POC) Testing

## PART B: REGIONAL MARKET PERSPECTIVE

-□Global Cardiac Biomarkers Market Overview by Geographic Region

### REGIONAL MARKET OVERVIEW

#### 6. North America

-□North American Cardiac Biomarkers Market Overview by Geographic Region

-□North American Cardiac Biomarkers Market Overview by Type

-□North American Cardiac Biomarkers Market Overview by Application

-□North American Cardiac Biomarkers Market Overview by Location of Testing

-□Country-wise Analysis of North American Cardiac Biomarkers Market

o□The United States

-□United States Cardiac Biomarkers Market Overview by Type

-□United States Cardiac Biomarkers Market Overview by Application

-□United States Cardiac Biomarkers Market Overview by Location of Testing

o□Canada

-□Canadian Cardiac Biomarkers Market Overview by Type

-□Canadian Cardiac Biomarkers Market Overview by Application

-□Canadian Cardiac Biomarkers Market Overview by Location of Testing

o□Mexico

-□Mexican Cardiac Biomarkers Market Overview by Type

-□Mexican Cardiac Biomarkers Market Overview by Application

-□Mexican Cardiac Biomarkers Market Overview by Location of Testing

#### 7. Europe

-□European Cardiac Biomarkers Market Overview by Geographic Region

-□European Cardiac Biomarkers Market Overview by Type

-□European Cardiac Biomarkers Market Overview by Application

-□European Cardiac Biomarkers Market Overview by Location of Testing

-□Country-wise Analysis of European Cardiac Biomarkers Market

o□Germany

-□German Cardiac Biomarkers Market Overview by Type

-□German Cardiac Biomarkers Market Overview by Application

-□German Cardiac Biomarkers Market Overview by Location of Testing

o□France

-□French Cardiac Biomarkers Market Overview by Type

-□French Cardiac Biomarkers Market Overview by Application

-□French Cardiac Biomarkers Market Overview by Location of Testing

o□The United Kingdom

-□United Kingdom Cardiac Biomarkers Market Overview by Type

-□United Kingdom Cardiac Biomarkers Market Overview by Application

-□United Kingdom Cardiac Biomarkers Market Overview by Location of Testing

o□Italy

-□Italian Cardiac Biomarkers Market Overview by Type

-□Italian Cardiac Biomarkers Market Overview by Application

-□Italian Cardiac Biomarkers Market Overview by Location of Testing

o□Spain

-□Spanish Cardiac Biomarkers Market Overview by Type

-□Spanish Cardiac Biomarkers Market Overview by Application

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-[]Spanish Cardiac Biomarkers Market Overview by Location of Testing  
o[]Rest of Europe

-[]Rest of Europe Cardiac Biomarkers Market Overview by Type

-[]Rest of Europe Cardiac Biomarkers Market Overview by Application

-[]Rest of Europe Cardiac Biomarkers Market Overview by Location of Testing

## 8. Asia-Pacific

-[]Asia-Pacific Cardiac Biomarkers Market Overview by Geographic Region

-[]Asia-Pacific Cardiac Biomarkers Market Overview by Type

-[]Asia-Pacific Cardiac Biomarkers Market Overview by Application

-[]Asia-Pacific Cardiac Biomarkers Market Overview by Location of Testing

-[]Country-wise Analysis of Asia-Pacific Cardiac Biomarkers Market

### o[]Japan

-[]Japanese Cardiac Biomarkers Market Overview by Type

-[]Japanese Cardiac Biomarkers Market Overview by Application

-[]Japanese Cardiac Biomarkers Market Overview by Location of Testing

### o[]China

-[]Chinese Cardiac Biomarkers Market Overview by Type

-[]Chinese Cardiac Biomarkers Market Overview by Application

-[]Chinese Cardiac Biomarkers Market Overview by Location of Testing

### o[]India

-[]Indian Cardiac Biomarkers Market Overview by Type

-[]Indian Cardiac Biomarkers Market Overview by Application

-[]Indian Cardiac Biomarkers Market Overview by Location of Testing

### o[]South Korea

-[]South Korean Cardiac Biomarkers Market Overview by Type

-[]South Korean Cardiac Biomarkers Market Overview by Application

-[]South Korean Cardiac Biomarkers Market Overview by Location of Testing

### o[]Rest of Asia-Pacific

-[]Rest of Asia-Pacific Cardiac Biomarkers Market Overview by Type

-[]Rest of Asia-Pacific Cardiac Biomarkers Market Overview by Application

-[]Rest of Asia-Pacific Cardiac Biomarkers Market Overview by Location of Testing

## 9. South America

-[]South American Cardiac Biomarkers Market Overview by Geographic Region

-[]South American Cardiac Biomarkers Market Overview by Type

-[]South American Cardiac Biomarkers Market Overview by Application

-[]South American Cardiac Biomarkers Market Overview by Location of Testing

-[]Country-wise Analysis of Asia-Pacific Cardiac Biomarkers Market

### o[]Brazil

-[]Brazilian Cardiac Biomarkers Market Overview by Type

-[]Brazilian Cardiac Biomarkers Market Overview by Application

-[]Brazilian Cardiac Biomarkers Market Overview by Location of Testing

### o[]Argentina

-[]Argentine Cardiac Biomarkers Market Overview by Type

-[]Argentine Cardiac Biomarkers Market Overview by Application

-[]Argentine Cardiac Biomarkers Market Overview by Location of Testing

### o[]Rest of South America

-[]Rest of South American Cardiac Biomarkers Market Overview by Type

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Rest of South American Cardiac Biomarkers Market Overview by Application
- Rest of South American Cardiac Biomarkers Market Overview by Location of Testing

#### 10. Rest of World

- Rest of World Cardiac Biomarkers Market Overview by Type
- Rest of World Cardiac Biomarkers Market Overview by Application
- Rest of World Cardiac Biomarkers Market Overview by Location of Testing

#### PART C: GUIDE TO THE INDUSTRY

#### PART D: ANNEXURE

1. RESEARCH METHODOLOGY
2. FEEDBACK

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Global Cardiac Biomarkers Market - Types, Applications and Testing Locations**

Market Report | 2025-08-01 | 256 pages | Industry Experts

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scottss-international.com

**ORDER FORM:**

| Select license | License                     | Price     |
|----------------|-----------------------------|-----------|
|                | Single user licence (PDF)   | \$4500.00 |
|                | Enterprise Electronic (PDF) | \$7200.00 |
|                |                             | VAT       |
|                |                             | Total     |

\*Please circle the relevant license option. For any questions please contact support@scottss-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|               |                      |                               |   |
|---------------|----------------------|-------------------------------|---|
| Email*        | <input type="text"/> | Phone*                        | <input type="text"/>                    |
| First Name*   | <input type="text"/> | Last Name*                    | <input type="text"/>                    |
| Job title*    | <input type="text"/> |                               |   |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/>                    |
| Address*      | <input type="text"/> | City*                         | <input type="text"/>                    |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/>                    |
|               |                      | Date                          | <input type="text" value="2026-02-22"/> |
|               |                      | Signature                     | <input type="text"/>                    |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scottss-international.com

www.scottss-international.com